Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience

Background: Lapelga(®) was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category. We explored the efficacy and tolerability of Lapelga(®) in a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Fahad, Black, Morgan, Charlton, Alaina, Younus, Jawaid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047890/
https://www.ncbi.nlm.nih.gov/pubmed/36975457
http://dx.doi.org/10.3390/curroncol30030244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047890/
https://www.ncbi.nlm.nih.gov/pubmed/36975457
http://dx.doi.org/10.3390/curroncol30030244

Ejemplares similares